Sanofi Consumer Healthcare India Limited announced the outcome of its Board meeting held on February 25, 2026. The Board approved the Audited Standalone Financial Statements for the quarter and the financial year ended December 31, 2025. Key actions included recommending a final dividend of ₹75/- per equity share and approving the re-appointment of the Cost Auditor for FY2026. The financial results indicate a Profit for the period of ₹2,401 Million for the full year ended December 31, 2025.
Key Outcomes of the Board Meeting
The Board of Directors of Sanofi Consumer Healthcare India Limited convened on Wednesday, February 25, 2026, transacting several key items regarding the company’s financial and statutory compliances.
Approval of Audited Financial Results
The Board considered and approved the Audited Standalone Financial Statements for both the quarter and the full financial year ending December 31, 2025. Accompanying documents, including the Auditor’s Report, Statement of Assets and Liabilities, and Cashflows statement, were enclosed.
The financial summary for the year ended December 31, 2025 (Audited) shows:
- Total Income: ₹8,968 Million (compared to ₹7,375 Million in FY2024).
- Profit for the period/year: ₹2,401 Million (compared to ₹1,810 Million in FY2024).
- Basic and diluted EPS (not annualised): ₹104.27 (compared to ₹78.59 in FY2024).
The statutory auditors, M/s. Kalyaniwalla & Mistry LLP, issued an audit report with an Unmodified Opinion on these results.
Dividend Recommendation
The Board recommended a final dividend of ₹75/- per equity share (Face Value of ₹10/- each) for the Financial Year ended December 31, 2025. This recommendation is subject to subsequent approval by the shareholders at the upcoming Annual General Meeting (AGM).
Cost Auditor Re-appointment
The Board also approved the re-appointment of M/s. Kishore Bhatia & Associates (Firm Registration Number – 00294) to serve as the Cost Auditor for the Financial Year ending December 31, 2026. The remuneration is subject to ratification by the shareholders.
Auditor’s Report and Financial Notes Highlights
Emphasis on Related Party Transactions
The Independent Auditor’s Report drew attention to Note 11 concerning material related party transactions involving the export of goods to Opella Healthcare International SAS. While an initial limit was approved, an enhancement was sought. The company executed exports of ₹111 million between October 10 and October 28, 2025, pending shareholder approval, which was subsequently obtained on October 29, 2025.
Other Notable Disclosures
The notes provided context on performance:
- Product Relaunches: Results are not fully comparable with the previous year due to the voluntary recall and subsequent relaunch of products like Depura Adult (Mar 2025), Combiflam Suspension (Jun 2025), and Allegra Suspension/Depura Kids (Sep 2025).
- Exceptional Items: The FY2025 results included a reversal of ₹66 Million related to demerger provisions made in the prior year. FY2024 exceptional items included ₹108 Million in product recall costs and inventory write-off.
- Labour Codes Impact: The company recognized an incremental financial impact of ₹24 Million as past service cost due to changes in wage definitions under the newly notified Four Labour Codes, effective November 21, 2025.
- Parent Company Change: Effective April 30, 2025, the ultimate parent changed from Sanofi to Opal JVco S.a.r.l following the global sale of the controlling stake to Clayton, Dubilier & Rice Fund XII, L.P.
Source: BSE
